Merck Plans Wilmington, Delaware, Biologics Operations
05/23/2025
The investment will include the construction of a 470,000-square-foot biologics center of excellence, located at the Chestnut Run Innovation and Science Park, which will feature laboratory, manufacturing and warehouse capabilities. Operations are scheduled to begin by 2028.
“The decision to build a new biologics facility in Wilmington demonstrates our commitment to advancing U.S. manufacturing and partnering in communities where our employees live and work,” said Sanat Chattopadhyay, executive vice president and president, Merck Manufacturing Division. “As a hub for life science, research and development, and pharmaceutical manufacturing, CRISP offers unparalleled opportunities for future expansion.”
Merck, doing business as Merck Sharp & Dohme or MSD outside the U.S. and Canada, develops and produces medicines, vaccines, biologic therapies and animal health products. The company’s blockbuster products include cancer immunotherapy, anti-diabetic medications, and vaccines for HPV and chickenpox.
“This new site in Delaware is on the cutting edge of innovation, helping lead the way as we transform medicine and technology,” noted Delaware Gov. Matt Meyer. “Merck is pioneering the next generation of care right here in Wilmington, and they couldn’t have picked a better place to do it. The positive impact this will have on Wilmington and the state of Delaware is exciting, and this is just the beginning.”
Project Announcements
AMI Metals Expands Spokane, Washington, Production Operations
06/20/2025
Newly Weds Foods Plans Dyersburg, Tennessee, Production Operations
06/20/2025
Yaskawa American Expands Franklin, Wisconsin, Headquarters Operations
06/19/2025
Cayuga Milk Ingredients Expands Cayuga County, New York, Production Operations
06/19/2025
Gap Upgrades Gallatin, Tennessee, Logistics Operations
06/19/2025
Swiss-Based Galderma Plans Miami, Florida, Headquarters Operations
06/19/2025
Most Read
-
20th Annual Area Development Gold and Silver Shovel Awards
Q2 2025
-
First Person: Joe Capes, CEO, LiquidStack
Q2 2025
-
The Legal Limits of DEI in Incentives Agreements, Hiring, and Contracting
Q2 2025
-
39th Annual Corporate & 21st Annual Consultants Surveys: What Business Leaders and Consultants Are Saying About Site Selection
Q1 2025
-
Top States for Doing Business in 2024: A Continued Legacy of Excellence
Q3 2024
-
Rethinking Life Sciences Site Selection in a Resilient and Dynamic Market
Q2 2025
-
The New Math Behind Mexico and U.S. Manufacturing Decisions
Q2 2025